Skip to main content
Veterinary Medicines

Fatrobendan 1.25 mg, chewable tablets for dogs

Authorised
  • Pimobendan

Product identification

Medicine name:
Fatrobendan 1.25 mg, chewable tablets for dogs
Fatrobendan 1,25 mg, μασώμενα δισκία για σκύλους
Active substance:
  • Pimobendan
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Pimobendan
    1.25
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QC01CE90
Authorisation status:
  • Valid
Authorised in:
  • Cyprus
Package description:
  • PVC/PE/PVdC/PE/PVC blister sealed with thermoheated aluminium foil containing 10 tablets.Pack-sizes:- Cardboard box containing 5 blisters of 10 tablets (50 tablets)
  • PVC/PE/PVdC/PE/PVC blister sealed with thermoheated aluminium foil containing 10 tablets.Pack-sizes:- Cardboard box containing 1 blister of 10 tablets (10 tablets)
  • PVC/PE/PVdC/PE/PVC blister sealed with thermoheated aluminium foil containing 10 tablets.Pack-sizes:- Cardboard box containing 10 blisters of 10 tablets (100 tablets)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A
Responsible authority:
  • Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment
Authorisation number:
  • CY00991V
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0571/001
Concerned member states:
  • Cyprus
  • Czechia
  • Greece
  • Lithuania
  • Poland
  • Portugal
  • Slovakia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 10/10/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."